Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement

[1]  J. Bousquet,et al.  Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing , 2020, Allergy, asthma & immunology research.

[2]  C. Bachert,et al.  Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma , 2018, Allergy.

[3]  Boleslaw Samolinski,et al.  Electronic Clinical Decision Support System for allergic rhinitis management: MASK e‐CDSS , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  J. Bousquet,et al.  Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management , 2018, Clinical and Translational Allergy.

[5]  O. Usmani,et al.  Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here? , 2018, The journal of allergy and clinical immunology. In practice.

[6]  A. Sheikh,et al.  Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy , 2018, Allergy.

[7]  A. Sheikh,et al.  EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.

[8]  A. Sheikh,et al.  Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview , 2018, Allergy.

[9]  A. Sheikh,et al.  The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study , 2018, Allergy.

[10]  P. Cullinan,et al.  Impact of Rhinitis on Work Productivity: A Systematic Review. , 2017, The journal of allergy and clinical immunology. In practice.

[11]  A. Sheikh,et al.  The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. , 2017, Journal of investigational allergology & clinical immunology.

[12]  E. Valovirta,et al.  Results from the 5‐year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy , 2017, The Journal of allergy and clinical immunology.

[13]  A. Leunig,et al.  Rhinology Future Debates, an EUFOREA Report. , 2017, Rhinology.

[14]  J. Bousquet,et al.  Non‐allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology , 2017, Allergy.

[15]  J. Bousquet,et al.  Work productivity in rhinitis using cell phones: The MASK pilot study , 2017, Allergy.

[16]  Joaquim Mullol,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision , 2017, The Journal of allergy and clinical immunology.

[17]  D. Ryan,et al.  Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement , 2017, Allergy.

[18]  W. Fokkens,et al.  Endotype-driven treatment in chronic upper airway diseases , 2017, Clinical and Translational Allergy.

[19]  John Appleby,et al.  A Terrible Beauty: A short history of NICE the National Institute for Health and Care Excellence , 2017 .

[20]  P Demoly,et al.  Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK‐rhinitis study , 2017, Allergy.

[21]  J. Bousquet,et al.  The Finnish Allergy Programme 2008–2018 works , 2017, European Respiratory Journal.

[22]  A. Sheikh,et al.  Allergen immunotherapy for allergic asthma: A systematic review and meta‐analysis , 2017, Allergy.

[23]  A. Leunig,et al.  Rhinology Future Debates, an EUFOREA Report. , 2017, Rhinology.

[24]  P. Hellings,et al.  Real-life study showing better control of allergic rhinitis by immunotherapy than regular pharmacotherapy. , 2017, Rhinology.

[25]  Todor A Popov,et al.  MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. , 2016, The Journal of allergy and clinical immunology.

[26]  J. Bousquet,et al.  MP‐AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children , 2016, Allergy.

[27]  J. Bousquet,et al.  AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation , 2016, European Respiratory Journal.

[28]  A. Sheikh,et al.  Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review , 2016, Clinical and Translational Allergy.

[29]  L. Cardell,et al.  TOTALL: high cost of allergic rhinitis—a national Swedish population-based questionnaire study , 2016, npj Primary Care Respiratory Medicine.

[30]  S. Simoens,et al.  Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review , 2014, Allergy.

[31]  G. Liss,et al.  AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. , 2014, The journal of allergy and clinical immunology. In practice.

[32]  P. Rombaux,et al.  Nationwide survey on immunotherapy practice by ENT specialists. , 2014, Rhinology.

[33]  N. Papadopoulos,et al.  Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology , 2013, Allergy.

[34]  J. Bousquet,et al.  Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? , 2013, Allergy.

[35]  C. Bachert,et al.  Prevalence of Allergic Sensitization versus Allergic Rhinitis Symptoms in an Unselected Population , 2012, International Archives of Allergy and Immunology.

[36]  G. Scadding,et al.  Nasal corticosteroid treatment reduces substance P levels in tear fluid in allergic rhinoconjunctivitis. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[37]  P. Hellings,et al.  Explorative study on patient’s perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis , 2012, Clinical and Translational Allergy.

[38]  Glenis K Scadding,et al.  Allergic rhinitis , 2018, Allergy, Asthma & Clinical Immunology.

[39]  G. Laekeman,et al.  Doelmatige behandeling van allergische aandoeningen (rhinoconjunctivitis, astma, anafylaxie op hymenopteragif), anafylaxie en angio-oedeem , 2010 .

[40]  G. Verleden,et al.  The impact of concomitant rhinitis on asthma‐related quality of life and asthma control , 2010, Allergy.

[41]  J. Bousquet,et al.  Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. , 2010, The Journal of allergy and clinical immunology.

[42]  Holger J Schünemann,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.

[43]  M. Kogevinas,et al.  Risk factors of new‐onset asthma in adults: a population‐based international cohort study , 2010, Allergy.

[44]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[45]  J. Bousquet,et al.  Allergic rhinitis and its consequences on quality of sleep: An unexplored area. , 2006, Archives of internal medicine.

[46]  D. Strachan,et al.  Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys , 2006, The Lancet.

[47]  C. Bachert,et al.  Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium , 2006, Allergy.

[48]  Benjamin Eng,et al.  Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective , 2006, Current medical research and opinion.

[49]  S. Durham,et al.  Prevalence and rate of diagnosis of allergic rhinitis in Europe , 2004, European Respiratory Journal.

[50]  J. Bousquet,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) , 2003 .

[51]  P. Demoly,et al.  ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France , 2002, Allergy.

[52]  S. Guerra,et al.  Rhinitis as an independent risk factor for adult-onset asthma. , 2002, The Journal of allergy and clinical immunology.

[53]  J. O'hanlon,et al.  Seasonal allergic rhinitis and antihistamine effects on children's learning , 1992, European Neuropsychopharmacology.

[54]  R. Settipane,et al.  Allergic rhinitis , 2005, Rhinology and Anterior Skull Base Surgery.